Cardiovascular Pharmacology

Published on 13/02/2015 by admin

Filed under Cardiothoracic Surgery

Last modified 13/02/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1560 times

Chapter 3 Cardiovascular Pharmacology

In this chapter the pharmacology of cardiovascular drugs that are used in the intensive care unit (ICU) is reviewed. Specific indications for particular drugs are discussed in other relevant chapters. Guidelines for the reintroduction of medications following routine cardiac surgery are provided in Chapter 17.


Inotropes and vasopressors are some of the most widely used drugs in the ICU, and they can be broadly classified on the basis of their effects on circulation. Inotropic drugs with vasodilatory effects (e.g., isoproterenol, milrinone, levosimendan) are termed inodilators; inotropic drugs with vasoconstrictive effects (e.g., norepinephrine) are termed inoconstrictors. Some drugs are inodilators at lower doses and inoconstrictors at higher doses (e.g., dopamine, epinephrine). Other drugs are pure vasoconstrictors or vasodilators. Vasoactive drugs can also be classified on the basis of their mechanism of action, for example, as sympathomimetics, phosphodiesterase inhibitors, or calcium sensitizers.

The effect of a drug on a vascular bed depends on the activity of the drug at various receptors and the relevant receptor population in that vascular bed. However, the overall effects of a drug on blood pressure, cardiac output, and regional blood flow depend on a complex interplay of factors, of which the direct pharmacologic properties of the drug is but one. Other relevant factors include:

For these reasons it is often difficult to predict the precise effect of a particular agent on an individual patient. These concepts are discussed in greater detail in the following material.

Infusions of vasoactive drugs are prescribed in different ways in different institutions. Three common methods are micrograms per kilogram per minute (μg/kg/min), micrograms per minute (μg/min), and milligrams per hour (mg/hr). In this book μg/kg/min is used. A conversion among the methods is provided in Appendix 1.


All sympathomimetics are derived from β-phenylethylamine. The presence of hydroxyl groups on the 3- and 4-carbons in the benzene ring designates a compound as a catecholamine, which may be endogenous or synthetic (Fig. 3-1). The noncatecholamine sympathomimetics include a diverse range of drugs, such as the asthma medication albuterol and the central nervous system stimulant amphetamine. Two commonly used vasoactive noncatecholamine sympathomimetics are ephedrine and phenylephrine.

Mechanism of Action

Sympathomimetics bind to and stimulate adrenergic receptors that are located on cell membranes. In 1948, Alquist described two adrenergic receptor subtypes, alpha (α) and beta (β), based on their relative responsiveness to norepinephrine, epinephrine, and isoproterenol.1 In the 1970s this classification was refined to include α1, α2, β1, and β2 receptor subtypes. Subsequently, further divisions of each receptor subtype have been discovered, but clinically useful drugs to exploit these expanded classifications have not been developed.

Adrenergic receptors are part of a family of receptors known as G protein coupled receptors. Receptor stimulation by an agonist (see Chapter 4) facilitates the binding of the nucleotide guanosine triphosphate to a G protein, which activates it. The activated G protein then stimulates or inhibits one of a number of second messenger systems. Two second messenger systems mediate the actions of adrenergic receptors:

Vasodilation β1 Heart

β2 Veins Vasodilation    

Individual Sympathomimetics


Dopamine is a precursor to norepinephrine and is itself an important neurotransmitter in the peripheral and central nervous systems. Dopamine stimulates α and β receptors and type 1 and 2 dopamine (DA) receptors. DA-1 receptors are found in the renal, mesenteric, and cerebral circulations,3 and their stimulation results in vasodilation. DA-1 receptors are also found in the renal tubule, where they mediate natriuresis. DA-2 receptors are analogous to α2 receptors in that they are found presynaptically and inhibit the release of norepinephrine. Dopamine also has an indirect mechanism of action.

At low doses (<3 μg/kg/min), dopaminergic effects predominate. At higher doses, initially β receptor effects predominate; then α receptor effects predominate. The widely accepted dose range is 3 to 10 μg/kg/min for β effects and more than 10 μg/kg/min for α effects. However, these dose ranges must be viewed with skepticism. There is huge individual variability in the pharmacokinetics of dopamine such that dramatically different plasma concentrations may occur in different patients who are receiving the same dose.4 Furthermore, the clinical effects of a given plasma concentration are dependent on the functional activity of the adrenergic receptors. β Receptors are desensitized in a variety of clinical settings, including after cardiac surgery and with heart failure.57 Because of its indirect action, dopamine has reduced effectiveness in patients with heart failure or shock. Despite these caveats, it is generally true that as the dose of dopamine increases, there is a progressive increase in blood pressure and heart rate.

Dopamine at a dose of 1 to 3 μg/kg/min has been termed “renal-dose dopamine” and has traditionally been used to provide selective renal vasodilation in patients at risk for renal dysfunction. However, it is now clear that although low-dose dopamine may increase blood flow to the renal cortex, blood flow to the renal medulla may actually decrease.8 Given the relatively hypoxic environment of the renal medulla under normal circumstances (Chapter 1), this effect is potentially harmful. Furthermore, the increase in urine output that occurs with low-dose dopamine is due primarily to a direct tubular natriuretic effect rather than to renal vasodilation. In a well-conducted, large, randomized trial, low-dose dopamine did not reduce the incidence of acute renal failure in patients with early renal dysfunction.9 Dopamine has a number of other potentially detrimental effects, including inhibition of hypoxic ventilatory drive, impairment of ventilation-perfusion matching in the lung, and suppression of the secretion of some anterior pituitary hormones, such as prolactin, growth hormone, and thyrotropin.8

Phosphodiesterase Type III Inhibitors

The phosphodiesterases (PDEs) are a family of enzymes that catalyze the breakdown of cyclic nucleotides, including cAMP and cGMP. There are multiple subtypes of PDE that have varying tissue distributions and actions.12 Caffeine and theophylline are nonspecific PDE inhibitors that are used as bronchodilators. Papaverine is a vasodilator and nonspecific PDE inhibitor that is used by cardiac surgeons during coronary artery bypass graft (CABG) surgery to prevent spasm of the internal mammary artery.

Drugs that selectively inhibit PDE subtype III function as inodilators. The commercially available PDE-III inhibitors all have a similar pharmacologic profile: they increase contractility and cause pulmonary and systemic (arteriolar and venous) vasodilation. As such, PDE-III inhibitors are useful for treating low cardiac output, particularly in the presence of pulmonary edema or pulmonary hypertension. They are potent vasodilators of coronary grafts13 and cause less tachycardia and atrial fibrillation than dobutamine.10 The inotropic effect is independent of the β1 receptor, which is advantageous in patients with β1 receptor desensitization (see earlier discussion). Also, by combining a PDE-III inhibitor with a β1 receptor agonist, a dual mechanism of action is exploited. Arteriolar and venous dilation can cause modest hypotension. This can be treated with either fluid or low-dose norepinephrine, depending on the status of the patient’s intravascular volume. In patients with cardiogenic shock, the combination of a PDE-III and norepinephrine provides support for both cardiac output and blood pressure, but without the troublesome tachycardia and metabolic disturbance that can occur with epinephrine.

PDE-III inhibitors are available as intravenous formulations for short-term use. Unlike the sympathomimetics, they have durations of action measured in hours, so their effects cannot be readily judged. Oral formulations of PDE-III inhibitors for the treatment of chronic heart failure have been studied but have resulted in higher mortality rates.14

Miscellaneous Vasoactive Drugs


An intravenous bolus dose of calcium chloride of 5 mg/kg (or 0.035 mmol/kg) increases blood pressure but has little effect on myocardial contractility.15 The duration of effect following a bolus dose is 5 to 10 minutes. The pressor effect is much more pronounced in the presence of hypocalcemia. Calcium chloride does not improve outcome after cardiac arrest16 and is no longer included in routine resuscitation protocols. However, calcium is useful in the management of hyperkalemia because it reduces potassium-induced arrhythmias, and in the treatment of hypocalcemia.


Vasopressin (V; antidiuretic hormone) is a peptide hormone released from the posterior pituitary in response to an increase in serum osmolarity or hypovolemia (Chapters 1 and Chapter 32). Stimulation of V1 receptors within vascular smooth muscle results in vasoconstriction (via the IP3/DAG second-messenger system), whereas stimulation of V2 receptors in the kidney results in water retention (via the cAMP second-messenger system). An additional action of vasopressin is to increase the release of the von Willebrand factor from the vascular endothelium, which increases platelet aggregation. The elimination half-time of vasopressin is 10 to 30 minutes.

Exogenously administered vasopressin is used to treat catecholamine-resistant vasodilatory shock. In early shock, endogenous stores of vasopressin are released from the posterior pituitary, but as shock progresses, these stores become depleted. In patients with advanced vasodilatory shock, vasopressin infusion at 4 units/hr combined with norepinephrine has been shown to be superior to norepinephrine alone in terms of hemodynamics and markers of splanchnic perfusion.17 However, higher doses of vasopressin, sufficient to replace rather than augment norepinephrine, can cause a marked reduction in cardiac output and may worsen splanchnic perfusion.18 In animal models, vasopressin is associated with relatively less vasoconstriction within the coronary, cerebral, and pulmonary circulations than is associated with catecholamines.19,20 Despite an antidiuretic effect, in patients with vasodilatory shock urine output may actually improve with vasopressin,21 presumably due to an improvement in renal blood flow. As with all vasoconstrictors, precipitous reductions in cardiac output can occur with vasopressin, particularly in the settings of hypovolemia and impaired ventricular function. Current recommendations are that vasopressin, in a dose of 0.01 to 0.04 units/min, should be considered in patients with vasodilatory shock who have adequate volume resuscitation and are refractory to high doses of catecholamines.22

β Blockers

β Blockers antagonize the effect of endogenous and exogenous sympathomimetics at β adrenergic receptors, thereby reducing heart rate and myocardial contractility. β Blockers can be broadly classified as nonselective (blockade of both β1 and β2 receptors) or as β1-receptor-selective. Some β blockers also have peripheral vasodilatory activity mediated by either α1 receptor blockade (e.g., carvedilol, labetalol) or β2 receptor stimulation (e.g., celiprolol).

β Blockers tend to be either lipid-soluble (e.g., metoprolol) or water-soluble (e.g., atenolol). Lipid-soluble agents typically undergo extensive hepatic metabolism and have a low oral bioavailability. Some lipid-soluble β blockers are metabolized by the cytochrome P-450 (CYP) 2D6 enzyme system, so their metabolism is susceptible to inhibition by other drugs (see Table 4-3). In contrast, water-soluble agents have high oral bioavailability and tend to be eliminated unchanged by the kidney. In patients with hepatic impairment, a water-soluble β blocker is appropriate, whereas in patients with renal impairment, a lipid-soluble β blocker may be more appropriate.

β Blockers have antihypertensive, antiarrhythmic, and antiischemic actions, and they inhibit ventricular remodeling. Treatment with β blockers is associated with reduced mortality rates in patients with coronary artery disease2528 and chronic heart failure (see Chapter 19) and in high-risk patients undergoing noncardiac surgery.29 In patients undergoing CABG surgery, preoperative treatment with β blockers is associated with reduced perioperative mortality rates.30 Acute cessation of chronic β blocker treatment can precipitate myocardial ischemia.31

In the cardiothoracic ICU, β blockers are used in the following circumstances:

The adverse effects of β blockers include bradycardia and AV block (particularly when used with digoxin, verapamil, or diltiazem); hypotension; acute ventricular decompensation; bronchospasm; and central nervous system effects such as headache and sleep disturbance. Central effects are potentially worse with lipid-soluble β blockers. Peripheral vascular effects are potentially worse with nonselective agents.

In patients with ventricular dysfunction, introduction of a β blocker may initially worsen the symptoms of heart failure. Ventricular remodeling and improved ejection fraction develop slowly over several months. Thus, β blockers should be avoided in patients who have only recently discontinued inotropic support or who are fluidoverloaded. Introduction of β blockers for the treatment of heart failure is generally not appropriate in the ICU. Characteristics of commonly used β blockers are listed in Table 3-2.


Buy Membership for Cardiothoracic Surgery Category to continue reading. Learn more here